FDA Grants J&J Accelerated Approval for Head and Neck Cancer Treatment
The FDA approved Johnson & Johnson’s treatment for patients with advanced head and neck cancer whose disease worsened after chemotherapy and immunotherapy.
The US Food and Drug Administration on Thursday granted accelerated approval to Johnson & Johnson's NYSE:JNJ treatment for patients with an advanced form of head and neck cancer whose disease has worsened after chemotherapy and immunotherapy.